Navigation Links
Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer

WAILEA, Hawaii and SUNNYVALE, Calif., June 27, 2007 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announced preliminary results from two open-label, multi-center Phase 2 clinical trials supporting the potential use of Xcytrin(R) (motexafin gadolinium) Injection, the company's lead product candidate, in combination with Alimta(R) (pemetrexed) and in combination with Taxotere(R) (docetaxel) as a second-line treatment for patients with non-small cell lung cancer (NSCLC) who failed at least one platinum-based chemotherapy regimen. The results were presented today at the Eighth International Lung Cancer Congress in Wailea, Hawaii.

The first ongoing study is evaluating Xcytrin plus Alimta and has enrolled 27 patients of which 20 are evaluable for response at this time. Patients are receiving 15mg/kg Xcytrin with a standard dose of Alimta and treatment is repeated every 21 days. Seventeen patients (85%) receiving Xcytrin and Alimta have achieved stabilization of their tumors, with 10 of the 17 still on treatment for up to nine cycles. The median survival time and median time to progression have not been reached, with estimated actuarial survival of 69% at 12 months. Patients still on treatment remain under evaluation for tumor response. The most common severe (Grade 3 or higher) side effects were asthenia (10.3%), pneumonia (10.3%), thrombocytopenia (10.3%), and neutropenia (6.9%).

The other ongoing study is evaluating Xcytrin plus Taxotere and has enrolled 24 patients of which 14 are evaluable for response at this time. Patients are given 15mg/kg Xcytrin with a standard dose of Taxotere and treatment is repeated every 21 days. Thirteen patients (87%) receiving Xcytrin and Taxotere have achieved stabilization of their tumors, with four still on treatment. The median survival time is 8.2 months and the median time to progression is 8.7 months. Patients still on treatment remain under evaluation for
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone

Post Your Comments:
(Date:11/6/2009)...RIS, November 6 , - Trial...olid for the,Treatment of Multi-Resistant Staphylo..., a speciality pharmaceutical company focused on t...designed to overcome the significant global,proble...s most advanced oral,antibacterial NXL103 (flopris...
(Date:11/5/2009)...RICHMOND, Calif., Nov. 5 ... a specialty pharmaceutical company focused on the...products that address important therapeutic needs ...ill host a webcast and teleconference with managem...s on Thursday, November 12, 2009, at 5:00 p.m. Eas...
(Date:11/5/2009)...TON, Calif., Nov. 5 Renee Cobos, M...rofessor of dermatology at the University of Calif...re experiencing tremendous results with Thermage C...r skin tightening and contouring, features a new v...acy and improves patient comfort. ,, "Thermage...
Breaking Medicine Technology:Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 3Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 4Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12 2Orange County Dermatologist Garners Outstanding Results With New Thermage CPT(R) 2Adding Drug Doesnt Help Control Blood Pressure 59997 1Adding Drug Doesnt Help Control Blood Pressure 59997 2Buffalo neurologists investigate possible new underlying cause of MS 59993 1Buffalo neurologists investigate possible new underlying cause of MS 59993 2Buffalo neurologists investigate possible new underlying cause of MS 59993 3Buffalo neurologists investigate possible new underlying cause of MS 59993 4Sex based prenatal brain differences found 10503 1Sex based prenatal brain differences found 10503 2
(Date:11/8/2009)... AARP Praises House Passage of Health Care Reform...n Medicare, improve coverage for all Americans ,...re/ -- ,, SUMMARY: Last night the United Sta...h care reform legislation that would strengthen Me...ance companies that prices millions of Americans o...
(Date:11/8/2009)... WASHINGTON, Nov. 8 Spe...ess conference following the House passage of H.R.... The bill passed by a vote of 220 to 215. Below ...ome of my colleagues just received a call from the...gratulating us on a great victory for the American...
(Date:11/8/2009)... Men’s Health Network (M...ealth risks, especially those linked to exposure t...military service. Bladder cancer is one of those c...s, especially those who once smoked or currently s...gton DC (PRWEB) November 8, 2009 -- Men’s He...
(Date:11/8/2009)... WASHINGTON, Nov. 7 USA...e Health Care for America Act, which will make hea...ance companies accountable and increase access to ...blic option. ,, "Teddy Roosevelt, FDR and Harry...ector Alan Charney. "Today,s vote ranks among our ...
(Date:11/8/2009)... Health Care Vote Shows Who Sides With Working Fa...Pa., Nov. 8 On the heel...epresentatives for a good, balanced health care re...coring of how our state,s U.S. representatives vot...ica Act. ,, The legislation, which passed Satu...
Breaking Medicine News(10 mins):Health News:AARP Pennsylvania Key Vote News Alert 2Health News:AARP Pennsylvania Key Vote News Alert 3Health News:AARP Pennsylvania Key Vote News Alert 4Health News:Veterans' Day Reminder from Men's Health Network: Pay Attention to Bladder Cancer Symptoms and Risk Factors 2Health News:Veterans' Day Reminder from Men's Health Network: Pay Attention to Bladder Cancer Symptoms and Risk Factors 3Health News:Robert Brady (D-PA-1), Chaka Fattah (D-PA-2), Kathy Dahlkemper (D-PA-3), Joe Sestak (D-PA-7), Patrick Murphy (D-PA-8), Christopher Carney (D-PA-10), John Murtha (D-PA-12), Paul Kanjorski (D-PA-11), Allyson Schwartz (D-PA-13), Mike Doyle (D-PA-14) Ge 2
...ng to the study conducted by Jennifer D. Thomas, a...e University it was found that alcohol exposure re...These kids develop fetal alcohol spectrum disorder...ssion symptoms, abnormal brain wave activity, fra...
...earch conducted by the scientist at the Monell Che...ism behind the detection of sweet// taste by human... saccharin used in high concentration it losses it...e mouth with water, resulting in the aftertaste ex...
...est figures compiled by National AIDS Control Orga... data collection strategy, have shown that an esti...th HIV. This clearly indicates that the number of ...ed by the deadly virus. It is estimated 38% of fem...
... Sally Field was just short of another milestone, ... had been diagnosed with Osteoporosis.//Osteoporos...inning of the bones which enhances the risk of bon...we are young is faster than bone loss. But this pr...
...ng to Libyan officials the five Bulgarian nurses a...eds of Libyan children with HIV will face a new tr...an foreign ministry said the trial in Libya would ...ere tortured into confessing. The allegation...
...t Coordinator Jan Vandemoortele and Lt. Gen. Nadee...n and Reconstruction Authority (ERRA) has announce...from the devastating earthquake. The new plan for ...itation system, skill training, teachers training ...
Other Medicine News:Health News:Alcohol Intake During Pregnancy Is Bad For The Baby’s Hear 2Health News:Understanding how humans detect sweet taste 2Health News:HIV/AIDS On The Rise In India 2Health News:Make No Bones About It: Actress Sally, Fields Osteoporosis Like A star! 2
PM-50 Pulse Oximeter
Pefakit Reptilase
Pefakit TAFI
Pefakit TAFI Calibrator/Control
Medicine Products: